SMYD2 and neoplasm: SMYD2 also methylates non-histone targets, for example, SMYD2 mono-methylates K370 in p53 to reduce the DNA-binding efficiency of p53 [21], and this protein also methylates K810 of RB1 or K313 of PTEN to enhance cell cycle progression or inactivate tumor suppression function of PTEN, respectively [29, 30].